The early-onset form, clinically diagnosed before 65 years of age, a polygenic form where only 10% of the early-onset cases are attributable to the altered gene expression of either amyloid precursor protein, presenilin-1 or presenilin-2, affecting about 1% of all AD patients. This evidence concerns the gene PSEN2 and Alzheimer disease.